0
Selected Reports |

Beneficial Effects of Treatment With Anti-IgE Antibodies (Omalizumab) in a Patient With Severe Asthma and Negative Skin-Prick Test Results

Maarten van den Berge, MD, PhD; Ronald G. Pauw, MD; Jan G. R. de Monchy, MD, PhD; Cees A. van Minnen, MD; Dirkje S. Postma, MD, PhD; Huib A. M. Kerstjens, MD, PhD
Author and Funding Information

From the Department of Pulmonology (Drs van den Berge, Pauw, van Minnen, Postma, and Kerstjens), and the Department of Allergology (Dr de Monchy), University Medical Center Groningen, Groningen, the Netherlands.

Correspondence to: Maarten van den Berge, MD, PhD, University Medical Center Groningen, Department of Pulmonology, Hanzeplein 1, 9700 RB, Groningen, The Netherlands; e-mail: m.van.den.berge@int.umcg.nl


For editorial comment see page 8

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2011 American College of Chest Physicians


Chest. 2011;139(1):190-193. doi:10.1378/chest.10-0128
Text Size: A A A
Published online

It is now well recognized that treatment with anti-IgE antibodies like omalizumab is a valuable option in patients with allergic asthma who remain symptomatic despite optimal treatment. To our knowledge, treatment with omalizumab in patients with nonallergic asthma has not been reported. We present and discuss a patient with severe asthma and elevated total IgE who had a negative radioallergosorbent (RAST) test result and a negative skin-prick test result; the patient showed a dramatic improvement with this treatment strategy.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J 2016;3():31813.
Anti-IgE and Biologic Approaches for the Treatment of Asthma. Handb Exp Pharmacol Published online Nov 19, 2016;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543